Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Oxid Med Cell Longev ; 2019: 2853534, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31011401

RESUMO

Salvianolic acid A (SAA) is a bioactive polyphenol extracted from Salviae miltiorrhizae Bunge, which possesses a variety of pharmacological activities. In our previous study, we have demonstrated that SAA effectively attenuates kidney injury and inflammation in an established animal model of 5/6 nephrectomized (5/6Nx) rats. However, there has been limited research regarding the antioxidative effects of SAA on chronic kidney disease (CKD). Here, we examined the antioxidative effects and underlying mechanisms of SAA in 5/6Nx rats. The rats were injected with SAA (2.5, 5, and 10 mg·kg-1·d-1, ip) for 28 days. Biochemical, flow cytometry, and Western blot analyses showed that SAA significantly increased the activities of total superoxide dismutase (T-SOD), glutathione peroxidase (GPx), and catalase (CAT) and lowered the levels of malondialdehyde (MDA), reactive oxygen species (ROS), and NADPH oxidase 4 (NOX-4) in a dose-dependent manner in 5/6Nx rats and in H2O2-induced HK-2 cells in vitro. Moreover, SAA enhanced the activation of the protein kinase B/glycogen synthase kinase-3ß/nuclear factor-erythroid-2-related factor 2 (Akt/GSK-3ß/Nrf2) signaling pathway in a dose-dependent manner and subsequently increased the expression of heme oxygenase-1 (HO-1) in the kidney of 5/6Nx rats, which were consistent with those obtained in H2O2-induced HK-2 cells in vitro shown by Western blot analysis. Furthermore, SAA significantly increased the expression of intranuclear Nrf2 and HO-1 proteins compared to HK-2 cells stimulated by LPS on the one hand, which can be enhanced by QNZ to some extent; on the other hand, SAA significantly lowered the expression of p-NF-κB p65 and ICAM-1 proteins compared to HK-2 cells stimulated by H2O2, which can be abrogated by ML385 to some extent. In conclusion, our results demonstrated that SAA effectively protects the kidney against oxidative stress in 5/6Nx rats. One of the pivotal mechanisms for the protective effects of SAA on kidney injury was mainly related with its antioxidative roles by activating the Akt/GSK-3ß/Nrf2 signaling pathway and inhibiting the NF-κB signaling pathway.


Assuntos
Ácidos Cafeicos/farmacologia , Rim/patologia , Lactatos/farmacologia , Fator 2 Relacionado a NF-E2/metabolismo , NF-kappa B/metabolismo , Nefrectomia , Estresse Oxidativo/efeitos dos fármacos , Substâncias Protetoras/farmacologia , Transdução de Sinais/efeitos dos fármacos , Animais , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Glicogênio Sintase Quinase 3 beta/metabolismo , Peróxido de Hidrogênio/toxicidade , Lipopolissacarídeos , Masculino , Modelos Biológicos , Proteínas Proto-Oncogênicas c-akt/metabolismo , Ratos Sprague-Dawley
2.
Acta Pharmacol Sin ; 39(12): 1855-1864, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29795135

RESUMO

Salvianolic acid A (SAA) is a minor phenolic carboxylic acid extracted from Salviae miltiorrhizae Bunge (Danshen). SAA exhibits a variety of pharmacological activities, such as antioxidative, anti-thrombotic, neuroprotective, and anti-fibrotic effects, as well as protection from myocardial ischemia and prevention of diabetes and other diseases. Furthermore, SAA has shown renal-protective effects in doxorubicin-induced nephropathy. However, there has been limited research regarding the effects of SAA and underlying mechanisms in chronic kidney disease (CKD). Here, we examined the effects and molecular mechanisms of SAA in an established animal model of 5/6 nephrectomized (5/6Nx) rats. The rats were injected with SAA (2.5, 5, and 10 mg/kg per day, intraperitoneally (ip)) for 28 days. SAA dose-dependently lowered the levels of urine protein, blood urea nitrogen, serum creatinine, plasma total cholesterol, and plasma triglycerides in 5/6Nx rats. Histological examination revealed that SAA dose-dependently attenuated renal pathological lesions, evidenced by reduced renal tubulointerstitial fibrosis by decreasing the expression levels of tumor growth factor-ß1 and α-smooth muscle actin in 5/6Nx rats. Moreover, SAA dose-dependently inhibited the activation of nuclear factor-κB (NF-κB) and p38 mitogen-activated protein kinase (MAPK) signaling pathways, subsequently attenuating the secretion of tumor necrosis factor-α and interleukin-1ß and inhibiting the expression of monocyte chemotactic protein-1, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in kidneys of 5/6Nx rats. The above results were consistent with those obtained in lipopolysaccharide-induced HK-2 cells in vitro (a recognized in vitro inflammatory model). In conclusion, our results demonstrated that SAA effectively attenuates kidney injury in 5/6Nx rats. The therapeutic effects of SAA on kidney injury can be attributed to its anti-inflammatory activities through inhibition of the activation of the NF-κB and p38 MAPK signaling pathways.


Assuntos
Ácidos Cafeicos/uso terapêutico , Lactatos/uso terapêutico , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Insuficiência Renal Crônica/prevenção & controle , Fator de Transcrição RelA/metabolismo , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo , Animais , Proteínas I-kappa B/metabolismo , Rim/patologia , Masculino , Ratos Sprague-Dawley , Insuficiência Renal Crônica/patologia
3.
J Neurol Sci ; 369: 109-118, 2016 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-27653874

RESUMO

NS1619, a calcium-activated potassium channel (Kca channel) activator, can selectively and time-dependently accelerate the formation of transport vesicles in both the brain tumor capillary endothelium and tumor cells within 15min of treatment and then increase the permeability of the blood-brain tumor barrier (BTB). However, the mechanism involved is still under investigation. Using a rat brain glioma (C6) model, the expression of caveolin-1, FoxO1 and p-FoxO1 protein were examined at different time points after intracarotid infusion of NS1619 at a dose of 30µg/kg/min. Internalization of Cholera toxin subunit (CTB) labeled fluorescently was monitored by flow cytometry. The expression of caveolin-1 and FoxO1 protein at tumor microvessels was enhanced and caveolae-mediated CTB endocytosis was increased by NS1619 infusion for 15min. Compared with the 15min group, the expression of caveolin-1 protein was significantly decreased and the level of phosphorylation of FoxO1 was significantly increased in the NS1619 2h group. In addition, inhibitors of reactive oxygen species (ROS) or PI3K or PKB significantly attenuated the level of FoxO1 phosphorylation and also increased the expression of caveolin-1 protein in Human Brain Microvascular Endothelial Cells (HBMECs) cocultured with human glioma cells (U87) 2h after NS1619 treatment. This led to the conclusion that NS1619-mediated transport vesicle increase is, at least partly, related to the ROS/PI3K/PKB/FoxO1 signaling pathway.


Assuntos
Antineoplásicos/uso terapêutico , Benzimidazóis/uso terapêutico , Caveolina 1/metabolismo , Células Endoteliais/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo , Transdução de Sinais/efeitos dos fármacos , Animais , Antineoplásicos/farmacologia , Benzimidazóis/farmacologia , Neoplasias Encefálicas/patologia , Artérias Carótidas/citologia , Caveolina 1/genética , Linhagem Celular Tumoral , Toxina da Cólera/metabolismo , Cromonas/farmacologia , Inibidores Enzimáticos/farmacologia , Glioma/patologia , Humanos , Masculino , Morfolinas/farmacologia , Ratos , Ratos Wistar , Fatores de Tempo , Ensaios Antitumorais Modelo de Xenoenxerto
4.
Neuropharmacology ; 75: 407-15, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23973310

RESUMO

Adenosine 5'-triphosphate-sensitive potassium channel (KATP channel) activator, minoxidil sulfate (MS), can selectively increase the permeability of the blood-tumor barrier (BTB); however, the mechanism by which this occurs is still under investigation. Using a rat brain glioma (C6) model, we first examined the expression levels of occludin and claudin-5 at different time points after intracarotid infusion of MS (30 µg/kg/min) by western blotting. Compared to MS treatment for 0 min group, the protein expression levels of occludin and claudin-5 in brain tumor tissue of rats showed no changes within 1 h and began to decrease significantly after 2 h of MS infusion. Based on these findings, we then used an in vitro BTB model and selective inhibitors of diverse signaling pathways to investigate whether reactive oxygen species (ROS)/RhoA/PI3K/PKB pathway play a key role in the process of the increase of BTB permeability induced by MS. The inhibitor of ROS or RhoA or PI3K or PKB significantly attenuated the expression of tight junction (TJ) protein and the increase of the BTB permeability after 2 h of MS treatment. In addition, the significant increases in RhoA activity and PKB phosphorylation after MS administration were observed, which were partly inhibited by N-2-mercaptopropionyl glycine (MPG) or C3 exoenzyme or LY294002 pretreatment. The present study indicates that the activation of signaling cascades involving ROS/RhoA/PI3K/PKB in BTB was required for the increase of BTB permeability induced by MS. Taken together, all of these results suggested that MS might increase BTB permeability in a time-dependent manner by down-regulating TJ protein expression and this effect could be related to ROS/RhoA/PI3K/PKB signal pathway.


Assuntos
Barreira Hematoencefálica/efeitos dos fármacos , Neoplasias Encefálicas/patologia , Glioma/patologia , Minoxidil/análogos & derivados , Transdução de Sinais/efeitos dos fármacos , Vasodilatadores/farmacologia , Animais , Barreira Hematoencefálica/fisiopatologia , Permeabilidade Capilar/efeitos dos fármacos , Permeabilidade Capilar/fisiologia , Claudinas/metabolismo , Relação Dose-Resposta a Droga , Impedância Elétrica , Inibidores Enzimáticos/farmacologia , Peroxidase do Rábano Silvestre/farmacocinética , Técnicas In Vitro , Masculino , Minoxidil/farmacologia , Transplante de Neoplasias , Fosfatidilinositol 3-Quinases/metabolismo , Ratos , Ratos Wistar , Espécies Reativas de Oxigênio/metabolismo , Transdução de Sinais/fisiologia , Proteína rhoA de Ligação ao GTP/metabolismo
5.
J Mol Neurosci ; 51(2): 344-51, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23494637

RESUMO

Curcumin (Cur) is a major active component of the food flavor turmeric isolated from the powdered dry rhizome of Curcuma longa Linn., which has been used in traditional Chinese medicine to ameliorate intracerebral ischemic damage and reduce brain edema. However, the effects of Cur on the disruption of the blood-brain barrier (BBB) induced by brain ischemia are still unclear. The effects of Cur on the disruption of BBB and changes of tight junction (TJ) proteins induced by oxygen glucose deprivation (OGD) were studied in BBB in vitro. The transendothelial electrical resistance and the flux of horseradish peroxidase in BBB in vitro were measured. The expression and localization of the TJ proteins occludin and zonula occludens-1 (ZO-1) were evaluated by Western blots and immunofluorescence microscopy. The protein levels of heme oxygenase-1 (HO-1) were also analyzed via Western blots. Cur attenuated OGD-induced disruption of paracellular permeability and increased the expression of HO-1 protein in rat brain microvascular endothelial cells (RBMECs). After administration of OGD, the expression of occludin and ZO-1 proteins was restored by Cur, and this effect was blocked by a HO-1 inhibitor, zinc protoporphyrin (ZnPP). Cur protects RBMECs against OGD-induced disruption of TJ and barrier dysfunction via the HO-1 pathway. We propose that Cur is capable of improving the barrier function of BBB under ischemic conditions and this beneficial effect might be reversed by a HO-1 inhibitor, ZnPP.


Assuntos
Barreira Hematoencefálica/efeitos dos fármacos , Permeabilidade Capilar/efeitos dos fármacos , Hipóxia Celular , Curcumina/farmacologia , Células Endoteliais/efeitos dos fármacos , Heme Oxigenase-1/metabolismo , Regulação para Cima , Animais , Encéfalo/irrigação sanguínea , Células Cultivadas , Células Endoteliais/metabolismo , Endotélio Vascular/citologia , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/metabolismo , Glucose/metabolismo , Heme Oxigenase-1/antagonistas & inibidores , Heme Oxigenase-1/genética , Microvasos/citologia , Oxigênio/metabolismo , Protoporfirinas/farmacologia , Ratos , Proteínas de Junções Íntimas/genética , Proteínas de Junções Íntimas/metabolismo
6.
J Mol Neurosci ; 48(1): 302-12, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22581438

RESUMO

The calcium-activated potassium channel (K (Ca) channel) activator, NS1619, has been shown to selectively and time-dependently increase the permeability of the blood-tumor barrier (BTB) by downregulating the expression of tight junction (TJ) protein. However, the role of signaling cascades in this process has not been precisely elucidated. This study was performed to determine the role of signaling cascades involving reactive oxygen species (ROS)/RhoA/PI3K/PKB in increasing the permeability of the BTB induced by NS1619. Using an in vitro BTB model and selective inhibitors of signaling pathways, we investigated whether ROS/RhoA/PI3K/PKB pathway plays a key role in the process of the increase in BTB permeability induced by NS1619. The results revealed that the BTB permeability was increased and the expression of TJ proteins were significantly decreased by NS1619, and selective inhibitors of identified signaling pathways reversed the observed alterations. Moreover, the significant increases in ROS, RhoA activity, and PKB phosphorylation after NS1619 administration were observed, which were partly inhibited by N-2-mercaptopropionyl glycine or C3 exoenzyme or LY294002 pretreatment. The present study demonstrates that the activation of signaling cascades involving ROS/RhoA/PI3K/PKB in rat brain microvascular endothelial cells was required for the increase in BTB permeability induced by NS1619.


Assuntos
Benzimidazóis/farmacologia , Barreira Hematoencefálica/efeitos dos fármacos , Neoplasias Encefálicas/tratamento farmacológico , Células Endoteliais/efeitos dos fármacos , Glioma/tratamento farmacológico , Transdução de Sinais/efeitos dos fármacos , Animais , Barreira Hematoencefálica/metabolismo , Neoplasias Encefálicas/irrigação sanguínea , Neoplasias Encefálicas/metabolismo , Permeabilidade Capilar/efeitos dos fármacos , Permeabilidade Capilar/fisiologia , Claudina-5/metabolismo , Células Endoteliais/metabolismo , Glioma/irrigação sanguínea , Glioma/metabolismo , Ocludina/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Canais de Potássio/agonistas , Canais de Potássio/metabolismo , Cultura Primária de Células , Proteínas Proto-Oncogênicas c-akt/metabolismo , Ratos , Espécies Reativas de Oxigênio/metabolismo , Transdução de Sinais/fisiologia , Junções Íntimas/efeitos dos fármacos , Junções Íntimas/metabolismo , Proteína rhoA de Ligação ao GTP/metabolismo
7.
Cell Mol Neurobiol ; 31(8): 1213-9, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21688124

RESUMO

This study was performed to investigate the mechanism of blood-brain barrier (BBB) permeability change, which was induced by aminoguanidine (AG) after surgical brain injury (SBI) in rats. Compared to control group, AG (150 mg/kg, i.p.) significantly reduced Evans blue extravasation into brain tissue at 24 h after surgical resection, it also induced a 32% decrease of malondialdehyde (MDA) values and a 1.1-fold increase of the glutathione (GSH) levels at 12 h after injury. The expression of inducible nitric oxide synthase (iNOS) reached the peak value at 24 h after SBI, which was significantly attenuated after AG treatment. In addition, ZO-1 protein was up-regulated by AG (150 mg/kg) treatment at 24 h after SBI. Our results indicated that AG could protect the BBB after SBI, which could be correlated with antioxidative property, the down-regulation of iNOS and up-regulation of tight junction protein expression.


Assuntos
Barreira Hematoencefálica/efeitos dos fármacos , Lesões Encefálicas/patologia , Guanidinas/farmacologia , Animais , Barreira Hematoencefálica/fisiologia , Lesões Encefálicas/metabolismo , Glutationa/metabolismo , Humanos , Masculino , Malondialdeído/metabolismo , Proteínas de Membrana/metabolismo , Óxido Nítrico Sintase Tipo II/metabolismo , Permeabilidade , Fosfoproteínas/metabolismo , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Proteína da Zônula de Oclusão-1
8.
Cell Mol Neurobiol ; 31(4): 629-34, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21331626

RESUMO

This study was performed to determine whether minoxidil sulfate (MS), a selective Adenosine 5'-triphosphate-sensitive potassium channel (K (ATP) channel) activator, has an effect on the expression of caveolin-1 in the rat's brain tumor tissue. Using a rat brain glioma (C6) model, we found that the expression of caveolin-1 protein at tumor sites was greatly increased after intracarotid infusion of MS at a dose of 30 µg/kg/min for 15, 30, and 60 min via Western blot analysis. And the peak value of the caveolin-1 expression was observed in rats with glioma after 15 min of MS perfusion, which was significantly attenuated by reactive oxygen species (ROS) scavenger (N-2-mercaptopropionyl glycine, MPG). In addition, MPG also significantly inhibited the increase of blood-brain tumor barrier (BTB) permeability which was induced by MS. This led to the conclusion that the MS-induced BTB permeability increase may be related to the accelerated formation of caveolin-1 protein, and could be mediated by ROS.


Assuntos
Neoplasias Encefálicas/metabolismo , Caveolina 1/metabolismo , Glioma/metabolismo , Canais KATP/metabolismo , Minoxidil/análogos & derivados , Regulação para Cima/efeitos dos fármacos , Animais , Barreira Hematoencefálica/efeitos dos fármacos , Neoplasias Encefálicas/irrigação sanguínea , Neoplasias Encefálicas/patologia , Capilares/efeitos dos fármacos , Capilares/metabolismo , Modelos Animais de Doenças , Azul Evans/metabolismo , Glioma/irrigação sanguínea , Glioma/patologia , Minoxidil/farmacologia , Permeabilidade/efeitos dos fármacos , Ratos , Ratos Wistar , Tiopronina/farmacologia
9.
Neurosci Lett ; 493(3): 140-4, 2011 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-21334421

RESUMO

This study was performed to investigate the mechanism of the blood-brain tumor-barrier (BTB) permeability increase, which was induced by NS1619, a selective K(Ca) channel activator. Using a rat brain glioma (C6) model, we exam the expression of ZO-1 and occludin in mRNA and protein level at different time point after intracarotid infusion of NS1619 (30 µg/kg/min) to tumor sites via RT-PCR and Western blot analysis. The mRNA and protein expression of ZO-1 and occludin had no great change before infusion and began to decrease significantly after 2 h NS1619 infusion, which was significantly attenuated by reactive oxygen species (ROS) scavenger (N-2-mercaptopropionyl glycine, MPG). In addition, MPG also significantly inhibited the increase of BTB permeability and malonaldehyde (MDA) level induced by NS1619. This led to the conclusion that NS1619 could time-dependently increase the BTB permeability by down-regulating the expression of tight junction protein, and this effect could be reversed by ROS.


Assuntos
Benzimidazóis/farmacocinética , Neoplasias Encefálicas/metabolismo , Regulação para Baixo/fisiologia , Glioma/metabolismo , Proteínas de Membrana/antagonistas & inibidores , Canais de Potássio Cálcio-Ativados/metabolismo , Junções Íntimas/metabolismo , Animais , Benzimidazóis/uso terapêutico , Barreira Hematoencefálica/efeitos dos fármacos , Barreira Hematoencefálica/metabolismo , Barreira Hematoencefálica/patologia , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/patologia , Permeabilidade da Membrana Celular/efeitos dos fármacos , Permeabilidade da Membrana Celular/genética , Modelos Animais de Doenças , Regulação para Baixo/efeitos dos fármacos , Glioma/tratamento farmacológico , Glioma/patologia , Masculino , Proteínas de Membrana/biossíntese , Proteínas de Membrana/genética , Ocludina , Fosfoproteínas/biossíntese , Canais de Potássio Cálcio-Ativados/agonistas , Ratos , Ratos Wistar , Espécies Reativas de Oxigênio/metabolismo , Junções Íntimas/efeitos dos fármacos , Junções Íntimas/patologia , Proteína da Zônula de Oclusão-1
10.
Brain Res ; 1259: 1-6, 2009 Mar 09.
Artigo em Inglês | MEDLINE | ID: mdl-19401176

RESUMO

This study was performed to determine whether dexamethasone (DEX) had an effect on calcium-activated potassium channels (KCa channels) in blood-brain tumor barrier (BTB).Using a rat brain glioma model, we found that the expression of KCa channels protein was significantly increased in brain tumor tissue. And bradykinin-induced increase of KCa channels protein was further enhanced after DEX pretreatment for 3 days. In addition, DEX pretreatment enhanced bradykinin-mediated up-regulation of the density of IKCa in the rat brain C6 cells in vitro BTB. Bradykinin markedly increased BTB permeability independent of DEX pretreatment. All of these results strongly suggest that DEX could regulate the target in the transcellular pathway of BTB-KCa channels.


Assuntos
Antineoplásicos Hormonais/farmacologia , Barreira Hematoencefálica/efeitos dos fármacos , Neoplasias Encefálicas/metabolismo , Encéfalo/efeitos dos fármacos , Dexametasona/farmacologia , Glioma/metabolismo , Canais de Potássio Cálcio-Ativados/metabolismo , Animais , Barreira Hematoencefálica/metabolismo , Bradicinina/farmacologia , Encéfalo/metabolismo , Neoplasias Encefálicas/tratamento farmacológico , Permeabilidade Capilar , Linhagem Celular Tumoral , Fármacos do Sistema Nervoso Central/farmacologia , Modelos Animais de Doenças , Feminino , Glioma/tratamento farmacológico , Potenciais da Membrana/efeitos dos fármacos , Transplante de Neoplasias , Distribuição Aleatória , Ratos , Ratos Wistar , Regulação para Cima/efeitos dos fármacos
11.
Neurosci Lett ; 452(2): 114-8, 2009 Mar 13.
Artigo em Inglês | MEDLINE | ID: mdl-19135131

RESUMO

This study was performed to determine whether dexamethasone (DEX) had an effect on calcium-activated potassium channels (K(Ca) channels) and Occludin protein in blood-brain tumor barrier (BTB). Using a rat brain glioma model, we found that the expression of K(Ca) channels protein and Occludin protein was significantly increased in brain tumor tissue after DEX treatment for 3 days. Compared with non-DEX-treated animals, Evans Blue levels were greatly attenuated in DEX-treated animals. These effects were significantly reversed by the glucocorticoid receptor antagonist RU38486. In addition, DEX treatment enhanced the density of I(KCa) in the rat brain microvascular endothelial cells (RBMECs) in vitro BTB. All of these results strongly suggest that DEX could be involved in the regulation of both transcellular and paracellular pathway.


Assuntos
Barreira Hematoencefálica/efeitos dos fármacos , Edema Encefálico/tratamento farmacológico , Neoplasias Encefálicas/complicações , Artérias Cerebrais/efeitos dos fármacos , Dexametasona/farmacologia , Animais , Anti-Inflamatórios/farmacologia , Barreira Hematoencefálica/fisiologia , Edema Encefálico/etiologia , Edema Encefálico/fisiopatologia , Artérias Cerebrais/metabolismo , Artérias Cerebrais/fisiopatologia , Modelos Animais de Doenças , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/metabolismo , Azul Evans , Feminino , Indicadores e Reagentes , Subunidades alfa do Canal de Potássio Ativado por Cálcio de Condutância Alta/efeitos dos fármacos , Subunidades alfa do Canal de Potássio Ativado por Cálcio de Condutância Alta/metabolismo , Proteínas de Membrana/efeitos dos fármacos , Proteínas de Membrana/metabolismo , Mifepristona/farmacologia , Ocludina , Ratos , Ratos Wistar , Receptores de Glucocorticoides/efeitos dos fármacos , Receptores de Glucocorticoides/metabolismo
12.
Neuroreport ; 20(2): 145-9, 2009 Jan 28.
Artigo em Inglês | MEDLINE | ID: mdl-19151597

RESUMO

The study was performed to investigate whether the ischemic gray matter and white matter show distinct patterns of aquaporin-4 (AQP4) expression in the reperfusion phase using an in-vivo transient spinal cord ischemia model in rats. We investigated to the time course of AQP4 expression at the blood-spinal cord interface by the quantitative immunogold and western blots methods. The results showed that disruption of AQP4 anchoring at the perivascular membrane did not lead to a net loss of protein. This is the first systematic and extensive study fully showing AQP4 expression dynamics after transient spinal cord ischemia and the findings are of major clinical and experimental interest.


Assuntos
Aquaporina 4/metabolismo , Isquemia do Cordão Espinal/metabolismo , Medula Espinal/metabolismo , Análise de Variância , Animais , Western Blotting , Imuno-Histoquímica , Masculino , Neuroglia/metabolismo , Ratos , Ratos Sprague-Dawley , Medula Espinal/irrigação sanguínea , Traumatismos da Medula Espinal/metabolismo
13.
Neurosci Lett ; 450(2): 172-5, 2009 Jan 30.
Artigo em Inglês | MEDLINE | ID: mdl-18983897

RESUMO

Bradykinin has been shown to increase the permeability of blood-tumor barrier (BTB) selectively. This study was performed to determine whether tumor necrosis factor-alpha (TNF-alpha) was involved in the regulation of this biological process. We found that the levels of TNF-alpha mRNA and heat shock factor-1 (HSF1) protein in C6 cells were markedly up-regulated by bradykinin via real-time RT-PCR and Western blot methods. And the most obvious increase of HSF1 protein and TNF-alpha mRNA in C6 cells were observed at 5 min and 10 min of bradykinin perfusion, respectively. In addition, the radioactivity of TNF-alpha in C6 cells' culture fluid also mostly increased at 15 min of bradykinin perfusion. And the Evans blue content of brain tumor tissues in rats and the concentration of TNF-alpha reached the maximum at 15 min of bradykinin perfusion. Our results suggested that the bradykinin-mediated BTB permeability increase is due to accelerated release of TNF-alpha, which could cause the increase of BTB permeability by promoting to the release HSF1 from neurospongioma cells.


Assuntos
Barreira Hematoencefálica/efeitos dos fármacos , Bradicinina/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Fator de Necrose Tumoral alfa/metabolismo , Animais , Barreira Hematoencefálica/fisiologia , Bradicinina/farmacologia , Neoplasias Encefálicas/metabolismo , Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/fisiopatologia , Permeabilidade Capilar/efeitos dos fármacos , Permeabilidade Capilar/genética , Linhagem Celular Tumoral , Chaperonina 10/genética , Chaperonina 10/metabolismo , Modelos Animais de Doenças , Masculino , Proteínas da Gravidez/genética , Proteínas da Gravidez/metabolismo , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , Fatores Supressores Imunológicos/genética , Fatores Supressores Imunológicos/metabolismo , Fatores de Tempo , Fator de Necrose Tumoral alfa/genética , Regulação para Cima/efeitos dos fármacos
14.
Brain Res ; 1246: 11-8, 2008 Dec 30.
Artigo em Inglês | MEDLINE | ID: mdl-18951883

RESUMO

The study investigated whether bradykinin (BK) preconditioning could regulate the expression of aquaporin-4 (AQP4) using an in vivo transient spinal cord ischemia model in rats. BK was infused continuously via the left femoral artery with infusion pump for 15 min (10 microg/kg/min) then we induced ischemia for 20 min and reperfusion for 24 and 72 h respectively. The results demonstrated that the central part of the white matter exhibited loss of perivascular AQP4 and showed a partial recovery toward 72 h of reperfusion. The border zone of white matter was different from the central part of the white matter by showing no loss of perivascular AQP4 at 24 h of reperfusion but rather a slight increase. BK significantly reduced the expression level of AQP4 protein in the white matter, but it had none of this effect in the gray matter region at 72 h post-reperfusion. There was no difference in AQP4 protein levels between BK group and control group at the two above-mentioned spinal cord regions at 24 h after reperfusion. In addition, the changes in AQP4 protein induced by BK preconditioning were obvious at 72 h after reperfusion, which were accompanied by a reduction of spinal cord edema. Our results demonstrated that the expression of AQP4 protein after spinal cord ischemia/reperfusion was region-specific, time-dependent and also indicated that the attenuation of AQP4 expression induced by BK could be one of the important molecular mechanisms in physiopathology of spinal cord ischemic edema.


Assuntos
Aquaporina 4/metabolismo , Bradicinina/farmacologia , Expressão Gênica , Isquemia/metabolismo , Traumatismos da Medula Espinal/metabolismo , Medula Espinal/irrigação sanguínea , Medula Espinal/metabolismo , Análise de Variância , Animais , Western Blotting , Modelos Animais de Doenças , Imuno-Histoquímica , Microscopia Eletrônica , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley
15.
Brain Res ; 1162: 1-8, 2007 Aug 08.
Artigo em Inglês | MEDLINE | ID: mdl-17618607

RESUMO

This study was performed to determine whether dexamethasone (DEX) had an effect on ATP-sensitive potassium channels (K(ATP) channels) in blood-brain tumor barrier (BTB). Using a rat brain glioma model, we found that DEX could significantly increase the expression of K(ATP) channels protein at tumor sites. And bradykinin-induced increase of K(ATP) channels protein was further enhanced after DEX pretreatment for 3 consecutive days via Western blots and immunohistochemistry methods. In addition, DEX pretreatment enhanced bradykinin-mediated increase of the density of I(KATP) in the cultured rat C6 glioma cells using the patch-clamp technique in a whole-cell configuration. DEX significantly decreased the BTB permeability, but it did not reduce bradykinin-mediated BTB permeability increase, which were significantly attenuated by the K(ATP) channel antagonist glibenclamide. This led to the conclusion that DEX-mediated change in BTB permeability is, at least partly, due to accelerated formation of K(ATP) channel, an important target in the biochemical regulation of this process.


Assuntos
Monofosfato de Adenosina/análogos & derivados , Antineoplásicos Hormonais/farmacologia , Barreira Hematoencefálica/efeitos dos fármacos , Neoplasias Encefálicas , Dexametasona/farmacologia , Glioma , Canais de Potássio Corretores do Fluxo de Internalização/metabolismo , Tionucleotídeos/farmacologia , Monofosfato de Adenosina/farmacologia , Análise de Variância , Animais , Bradicinina/farmacologia , Neoplasias Encefálicas/metabolismo , Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/secundário , Linhagem Celular Tumoral , Modelos Animais de Doenças , Interações Medicamentosas , Feminino , Glioma/metabolismo , Glioma/patologia , Glioma/secundário , Potenciais da Membrana/efeitos dos fármacos , Potenciais da Membrana/fisiologia , Potenciais da Membrana/efeitos da radiação , Técnicas de Patch-Clamp , Permeabilidade/efeitos dos fármacos , Canais de Potássio Corretores do Fluxo de Internalização/agonistas , Canais de Potássio Corretores do Fluxo de Internalização/antagonistas & inibidores , Ratos , Ratos Wistar , Ensaios Antitumorais Modelo de Xenoenxerto
16.
Brain Res ; 1144: 33-41, 2007 May 04.
Artigo em Inglês | MEDLINE | ID: mdl-17331483

RESUMO

Bradykinin has been shown to selectively transiently increase the permeability of the blood-brain barrier (BBB). This study was performed to determine whether ATP-sensitive potassium (K(ATP)) channels mediate the increase in permeability of brain tumor microvessels induced by BK. Using a rat brain glioma (C6) model, we found increased expression of K(ATP) channels at tumor sites via Western blot analysis, after intracarotid infusion of bradykinin at a dose of 10 microg/kg/min for 15 min. A significant increase (73.58%) of the integrated density value (IDV) of the K(ATP) channel Kir6.2 subunit was observed in rats with glioma after 10 min of bradykinin perfusion. The over-expression of K(ATP) channels with bradykinin was significantly attenuated by the K(ATP) channel antagonist glibenclamide. Immunohistochemistry and immunolocalization experiments showed that the over-expression of K(ATP) channels was more obvious near tumor capillaries of 10 microm in diameter. I(KATP) modulation by bradykinin in cultured C6 cells was also studied using the patch-clamp technique in a whole-cell configuration. Administration of bradykinin led to a significant opening of K(ATP) channels in a time-dependent manner. This led to the conclusion that the bradykinin-mediated BBB permeability increase is due to accelerated formation of K(ATP) channels, which are thus as an important target in the biochemical regulation of this process.


Assuntos
Trifosfato de Adenosina/farmacologia , Barreira Hematoencefálica/efeitos dos fármacos , Bradicinina/farmacologia , Glioma/irrigação sanguínea , Glioma/metabolismo , Canais de Potássio Corretores do Fluxo de Internalização/fisiologia , Animais , Linhagem Celular Tumoral , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Glioma/fisiopatologia , Glibureto/farmacologia , Potenciais da Membrana/efeitos dos fármacos , Potenciais da Membrana/fisiologia , Potenciais da Membrana/efeitos da radiação , Metástase Neoplásica/tratamento farmacológico , Técnicas de Patch-Clamp/métodos , Permeabilidade/efeitos dos fármacos , Bloqueadores dos Canais de Potássio/farmacologia , Ratos , Ratos Wistar , Fatores de Tempo , Ensaios Antitumorais Modelo de Xenoenxerto
17.
Neurosci Lett ; 413(2): 126-31, 2007 Feb 14.
Artigo em Inglês | MEDLINE | ID: mdl-17240062

RESUMO

This study investigated whether dexamethasone (DEX) treatment could regulate the expression of aquaporin-4 (AQP4) in rats with intracerebral hemorrhage (ICH). The results demonstrated that DEX significantly reduced AQP4 mRNA level in the perihematomal area compared with control group, but it increased the level in the brain area surrounding the third ventricle at day 1 post-ICH. There was no difference in AQP4 protein levels between DEX group and control group at the two above-mentioned brain regions at day 1 after ICH. The changes in AQP4 protein induced by DEX were marked at day 3 following surgery and still lasted at day 5 post-ICH, which were accompanied by a reduction of brain edema. Our results demonstrated that the expression of AQP4 protein after ICH was region-specific, time-dependent, and also indicated that DEX-induced cerebral edema clearance was correlated with the regulation of AQP4 expression in different brain regions.


Assuntos
Aquaporina 4/efeitos dos fármacos , Barreira Hematoencefálica/efeitos dos fármacos , Edema Encefálico/tratamento farmacológico , Hemorragia Cerebral/tratamento farmacológico , Dexametasona/farmacologia , Animais , Anti-Inflamatórios/farmacologia , Anti-Inflamatórios/uso terapêutico , Aquaporina 4/genética , Aquaporina 4/metabolismo , Barreira Hematoencefálica/metabolismo , Barreira Hematoencefálica/fisiopatologia , Edema Encefálico/etiologia , Edema Encefálico/fisiopatologia , Hemorragia Cerebral/complicações , Hemorragia Cerebral/fisiopatologia , Dexametasona/uso terapêutico , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/fisiologia , Masculino , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , Telencéfalo/irrigação sanguínea , Telencéfalo/efeitos dos fármacos , Telencéfalo/fisiopatologia , Terceiro Ventrículo/anatomia & histologia , Terceiro Ventrículo/fisiologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA